[The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
The presence of aluminum bone disease can be predicted by a rise in serum aluminum of > or = 50 microg/L following DFO challenge combined with plasma levels of intact PTH of < 150 pg/mL. However, the gold standard for the diagnosis of aluminum bone disease is a bone biopsy showing adynamic bone or osteomalacia. The dialysate concentration of aluminum should be maintained at < 10 microg/L and baseline levels of serum aluminum should be < 20 microg/L. In symptomatic patients with serum aluminum levels > 60 microg/L but < 200 microg/L or a rise of aluminum after DFO > 50 microg/L, DFO should be given to treat the aluminum overload.